Tag Archives: endp

Auxilium Mulls Endo Bid; Street Eyes A Higher Price

Specialty drugmaker Auxilium Pharmaceuticals (AUXL) adopted a poison-pill provision Wednesday to fend off a possible hostile bid from Endo International (ENDP), the morning after Endo announced an unsolicited $2.2 billion bid for Auxilium. Nonetheless, Auxilium said that it would review the offer, which comes to 28.10 a share, and the market certainly seemed to be rooting for it: Auxilium stock jumped 42% to a six-month high on the stock market

Forest Buying Aptalis; Teva Bids For NuPathe Vs. Endo

Drug stocks were moving on merger news in the stock market today as Forest Laboratories (FRX) forestalled an IPO and NuPathe (PATH) looked to start a bidding war between Endo Health Solutions (ENDP) and Teva Pharmaceutical Industries (TEVA). Forest Labs agreed to pay $2.9 billion for Aptalis, a drugmaker that filed to go public on Dec. 26 after a major reworking by the private equity group TPG Capital. It traded as Axcan Pharma until 2007, when

Endo Health Downgraded On Weak Zecuity Outlook

Cantor Fitzgerald on Thursday downgraded Endo Health Solutions (ENDP) to sell, sending shares down more than 2% in the stock market today. Analyst Irina Rivkind wrote in a research note that the company probably won’t be able to make further cost cuts unless it sells its American Medical Systems unit, and that upcoming drug launches will face stiff competition. She was particularly negative on the migrain patch Zecuity, which Endo will acquire